DRREDDY.NS - Dr. Reddy's Laboratories Limited

NSE - NSE Real Time Price. Currency in INR
2,126.10
-24.05 (-1.12%)
At close: 12:29PM IST
Stock chart is not supported by your current browser
Previous Close2,150.15
Open2,151.45
Bid2,126.05 x 0
Ask2,127.00 x 0
Day's Range2,120.05 - 2,155.95
52 Week Range1,901.15 - 2,787.00
Volume120,057
Avg. Volume539,532
Market Cap352.108B
Beta0.14
PE Ratio (TTM)35.64
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield20.00 (0.95%)
Ex-Dividend Date2017-07-17
1y Target EstN/A
  • Where Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Stands In Terms Of Earnings Growth Against Its Industry
    Simply Wall St.2 days ago

    Where Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Stands In Terms Of Earnings Growth Against Its Industry

    After looking at Dr Reddy’s Laboratories Limited’s (NSEI:DRREDDY) latest earnings update (31 December 2017), I found it helpful to revisit the company’s performance in the past couple of years andRead More...

  • Dr Reddy’s Laboratories Limited (NSE:DRREDDY): Time For A Financial Health Check
    Simply Wall St.29 days ago

    Dr Reddy’s Laboratories Limited (NSE:DRREDDY): Time For A Financial Health Check

    Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Dr Reddy’s Laboratories Limited (NSEI:DRREDDY), with a market cap of ₹348.85B, are often out ofRead More...

  • Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
    Zackslast month

    Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

    Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

  • Does Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) PE Ratio Warrant A Sell?
    Simply Wall St.2 months ago

    Does Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) PE Ratio Warrant A Sell?

    Dr Reddy’s Laboratories Limited (NSEI:DRREDDY) is currently trading at a trailing P/E of 36.5x, which is higher than the industry average of 29.5x. While this makes DRREDDY appear like aRead More...

  • Will Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Continue To Underperform Its Industry?
    Simply Wall St.3 months ago

    Will Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Continue To Underperform Its Industry?

    Dr Reddy’s Laboratories Limited (NSEI:DRREDDY) delivered a less impressive 9.50% ROE over the past year, compared to the 13.67% return generated by its industry. Though DRREDDY’s recent performance is underwhelming,Read More...

  • Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y
    Zacks3 months ago

    Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y

    Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.

  • Associated Press3 months ago

    Doctor Reddy's posts 3Q profit

    The Hyderabad, India-based company said it had profit of 32 cents per share. Earnings, adjusted for pretax expenses, were 41 cents per share. The pharmaceutical posted revenue of $596 million in the period. ...

  • Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) Earnings Grew 6.9% In A Year. Was It Better Than Its Long-Term Trend?
    Simply Wall St.4 months ago

    Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) Earnings Grew 6.9% In A Year. Was It Better Than Its Long-Term Trend?

    Measuring Dr Reddy’s Laboratories Limited’s (NSEI:DRREDDY) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met orRead More...

  • How Do Analysts See Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Performing Over The Couple Of Years?
    Simply Wall St.4 months ago

    How Do Analysts See Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Performing Over The Couple Of Years?

    The latest earnings release Dr Reddy’s Laboratories Limited’s (NSEI:DRREDDY) announced in September 2017 suggested that the company experienced a significant headwind with earnings deteriorating by -39.84%. Today I want toRead More...

  • Reuters4 months ago

    Dr. Reddy's resolves U.S. probe over child safety of drug packaging

    The settlement was disclosed in documents filed in federal court in Trenton, New Jersey, over a year after the U.S. Consumer Product Safety Commission voted to refer a case involving the drugmaker to the U.S. Justice Department. Dr. Reddy's in a statement said that the safety of patients and consumers was of "paramount importance" to the company. It said it disagreed with the allegations but agreed to the settlement to avoid prolonged litigation.

  • Reuters4 months ago

    Dr. Reddy's resolves U.S. probe over child safety of drug packaging

    Dr. Reddy's Laboratories Ltd will pay $5 million to resolve U.S. claims that the Indian company sold prescription drugs in the United States in packaging that was not tested for child safety, according to court papers filed on Monday. The settlement was disclosed in documents filed in federal court in Trenton, New Jersey, over a year after the U.S. Consumer Product Safety Commission voted to refer a case involving the drugmaker to the U.S. Justice Department. Dr. Reddy's in a statement said that the safety of patients and consumers was of "paramount importance" to the company.

  • Is Dr Reddy’s Laboratories Limited (NSE:DRREDDY) A Financially Sound Company?
    Simply Wall St.4 months ago

    Is Dr Reddy’s Laboratories Limited (NSE:DRREDDY) A Financially Sound Company?

    Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Dr Reddy’s Laboratories Limited (NSEI:DRREDDY) with a market-capitalization of ₹363.73B, rarely draw their attention and few analystsRead More...

  • Reuters5 months ago

    Exclusive: Prescient messages about Indian companies circulate in WhatsApp groups

    Three days before Dr. Reddy's Laboratories Ltd announced quarterly results this summer, a message circulated on a private WhatsApp group saying the Indian drugmaker would not post good numbers. Dr. Reddy's was going to report a loss, according to the message on the "Market Chatter" group, which was posted on July 24 from a mobile phone number that Reuters traced back to Nishant Vass, an auto analyst at ICICI Securities, a leading Indian brokerage. The WhatsApp group had 45 members, mostly traders.

  • Reuters5 months ago

    Exclusive: Prescient messages about Indian companies circulate in WhatsApp groups

    Three days before Dr. Reddy's Laboratories Ltd announced quarterly results this summer, a message circulated on a private WhatsApp group saying the Indian drugmaker would not post good numbers. Dr. Reddy's was going to report a loss, according to the message on the "Market Chatter" group, which was posted on July 24 from a mobile phone number that Reuters traced back to Nishant Vass, an auto analyst at ICICI Securities, a leading Indian brokerage. The WhatsApp group had 45 members, mostly traders.

  • Dr. Reddy's Laboratories (RDY) Surges: Stock Moves 5.7% Higher
    Zacks7 months ago

    Dr. Reddy's Laboratories (RDY) Surges: Stock Moves 5.7% Higher

    Dr. Reddy's Laboratories (RDY) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes.

  • Reuters7 months ago

    Indivior files patent lawsuits against generic Suboxone rivals

    Indivior said on Friday its U.S. subsidiary has filed patent lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of Indivior's revenue. The lawsuits were filed against Dr. Reddy's, Allergan Plc's Actavis Laboratories, Endo International's Par Pharmaceutical, Alvogen Pharma US, Teva Pharmaceutical Industries and Mylan NV.

  • Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise
    Zacks9 months ago

    Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise

    Dr. Reddy's Laboratories Ltd.'s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.

  • Associated Press9 months ago

    Doctor Reddy's posts 1Q profit

    On a per-share basis, the Hyderabad, India-based company said it had net income of 6 cents. The pharmaceutical posted revenue of $513 million in the period. Doctor Reddy's shares have dropped 15 percent ...

  • Reuters11 months ago

    India's drugmakers need more time to meet intl standards-industry group

    India's big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official. The lengthy timeline is a concern not only in India but around the world, as India's pharmaceutical firms supply a third of the drugs sold in the United States and a large percentage in other countries.

  • Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q4
    Zacks11 months ago

    Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q4

    Dr. Reddy's Laboratories Ltd. (RDY) reported fourth-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 29 cents, down from 7 cents in the year-ago quarter.

  • Associated Press11 months ago

    Doctor Reddy's posts 4Q profit

    On a per-share basis, the Hyderabad, India-based company said it had net income of 29 cents. The pharmaceutical posted revenue of $548 million in the period. For the year, the company reported profit of ...